We are using OMOP as the CDM for data standardization as part of the Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology (HARMONY), a pan-European IMI project aiming to collect, share and harmonize Big Data from multidisciplinary sources, including clinical and molecular data, in order to:
• Enable identification of novel pathways for drug development.
• Facilitate drug development pipelines and accelerate the “bench-to-bedside” process in drug development.
• Empower clinicians, policy makers and payers to improve decision-making and optimize care for patients with HM's.
In the context of hematologic malignancies, but extendable to other conditions, some more specific use cases could be:
• Determine the genomic differences between patients belonging to different age groups and their potential impact on the disease course
• Improved molecular characterization for refining current disease classifications and prognostic systems
• Definition of genetic markers and potential novel therapeutic strategies
• Identification of clinical and molecular markers for treatment response, outcome after relapse, potential toxicity…
• Explore the potential value of the variant allele frequency as measurement of minimal residual disease
So far we also have somatic variants obtained through targeted NGS, which fit the current G-CDM prototype (although not converted yet).
I hope this is helpful.